GenSight Biologics
Developing innovative gene therapies to preserve or restore vision in patients with retinal diseases.
About
GenSight Biologics is a biotechnology company advancing gene therapy for neurodegenerative ophthalmic diseases. They are developing treatments for conditions like Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa (RP), and Geographic Atrophy in Dry-AMD, utilizing technologies such as gene therapy, mitochondrial targeting sequences, and optogenetics. Their clinical development includes GS010 (lenadogene nolparvovec) and GS030. Teams look it up for Biotechnology, Healthcare, Gene Therapy.
Frequently asked
What does GenSight Biologics do?
GenSight Biologics is a Biotechnology company that offers Services. Teams look it up for Healthcare, Gene Therapy, Ophthalmology. It is based in Paris, France and was founded in 2012. Public records show $5M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has GenSight Biologics raised?
GenSight Biologics has raised a total of $5M in funding. The most recent round on record is Unknown.
Where is GenSight Biologics headquartered?
GenSight Biologics is headquartered in Paris, France.
When was GenSight Biologics founded?
GenSight Biologics was founded in 2012.
What industry does GenSight Biologics operate in?
GenSight Biologics operates in Biotechnology, Healthcare, Gene Therapy, Ophthalmology.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.